Will NuvaRing Be Recalled From the Market Due to the Blood Clot Risk from the Birth Control Ring?
Despite a growing number of lawsuits filed by former users and mounting evidence linking side effects of NuvaRing birth control to an increased risk of blood clots, there is no indication that NuvaRing will be removed from the market in the immediate future.
Please note that the lawyers at Saiontz & Kirk, P.A. are no longer taking on new cases involving NuvaRing. The content on this page is provided for informational purposes only.
NuvaRing is a birth control ring that is inserted once a month into the vagina to prevent pregnancy through the release a combination of the estrongen hormone ethinyl estradiol (EE) and the third generation progestin etonogestrel. It is often prescribed as an alternative to oral birth control pills.
The lawyers at Saiontz & Kirk, P.A. represent women throughout the United States who are pursuing financial compensation through a NuvaRing lawsuit as a result of the manufacturer’s failure to properly research the effects of the birth control ring or adequately warn that the risk of suffering a stroke, heart attack, pulmonary embolism, deep vein thrombosis (DVT) or other blood clot injury may be higher with NuvaRing.
During an FDA advisory committee meeting in December 2011, independent advisors to the FDA reviewed the risk of blood clots with NuvaRing and other newer forms of contraceptives. Although data released by the FDA prior to the meetings suggested that women may face a 56% higher risk of blood clots with NuvaRing when compared to use of older birth control pills, the panel did not recommend a recall be issued to remove NuvaRing from the market.
Although there are serious and potentially life-threatening risks associated with NuvaRing, many in the medical community believe that it remains a viable alternative for women concerned about increasing their risk of pregnancy due to forgetting to take a daily birth control pill. Therefore, the FDA is unlikely to require a NuvaRing recall be issued.
Allowing NuvaRing to remain on the market does not diminish the product liability lawsuits being pursued by women who have suffered an injury. The manufacturer still had a duty to provide sufficient warnings for women to determine whether they were willing to accept the increased risk of blood clots before deciding to use the birth control ring.
Several studies released in 2012 demonstrated that side effects of NuvaRing pose a greater risk than the drug makers have disclosed, with women potentially facing double the risk of venous thrombosis when compared to women taking some older birth control pills containing levonorgestrel.